Lanterne Dx

Lanterne Dx (LDX) is a comprehensive histopathology CRO offering pre-clinical discovery, translational, and clinical biomarker services. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization, and validation. Key capabilities include immunohistochemistry (IHC), immunofluorescence (IF), multiplexing, in situ hybridization (ISH), fluorescence in situ hybridization (FISH), and a wide range of microscopic applications. These services are complemented by both qualitative and quantitative pathology evaluations, advanced image analysis, and comprehensive data analysis—all designed to streamline and accelerate drug development efforts. At Lanterne Dx, we are dedicated to being your trusted partner throughout the drug development journey, offering expert guidance and solutions to meet your needs.